Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896642 | 0.88 | HDAC1 (0.67) | TRPV1HDAC1 | |
| SCHEMBL14182618 | 0.85 | TRPV1 (0.53) | TRPV1HDAC1 | |
| SCHEMBL3617701 | 0.84 | TRPV1 (0.53) | TRPV1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3618243 | 0.84 | TRPV1 (0.60) | TRPV1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4898389 | 0.83 | TRPV1 (0.48) | TRPV1MEN1NPC1RAB9ABLM | |
| SCHEMBL4897389 | 0.80 | PDE4A (0.52) | TRPV1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14083477 | 0.78 | TRPV1 (0.56) | TRPV1MEN1NPC1RAB9ABLM | |
| SCHEMBL4891217 | 0.76 | TRPV1 (0.49) | TRPV1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL21973538 | 0.76 | PTGS1 (0.46) | TRPV1MAPT | |
| SCHEMBL13869175 | 0.76 | PTGS1 (0.46) | TRPV1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | TRPV1 2105/4885MEN1 1012/4885NPC1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.